Description: Alpine Immune Sciences, Inc., a development-stage specialty pharmaceutical company, engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. It is developing ALPN-101, an ICOS/CD28 antagonist program for the treatment of inflammatory diseases. The company is based in Seattle, Washington.
Home Page: www.alpineimmunesciences.com
ALPN Technical Analysis
188 East Blaine Street
Seattle,
WA
98102
United States
Phone:
206 788 4545
Officers
| Name | Title |
|---|---|
| Dr. Mitchell H. Gold M.D. | Exec. Chairman & CEO |
| Dr. Stanford Peng M.D., Ph.D. | Pres and Head of R&D |
| Mr. Paul Rickey | Sr. VP, CFO, Treasurer & Sec. |
| Dr. Wayne R. Gombotz | Chief Technology Officer |
| Temre Johnson | Head of IR & Corp. Communications |
| Dr. Remy Durand Ph.D. | Chief Bus. Officer |
| Dr. Pamela Holland Ph.D. | Sr. VP of Research |
| Dr. Andrew Seth Sandler M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5237 |
| Price-to-Sales TTM: | 9.423 |
| IPO Date: | 2015-06-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 85 |